Kidney Transplantation - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 143 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Kidney Transplantation - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Kidney Transplantation - Pipeline Review, H2 2014', provides an overview of the Kidney Transplantation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplantation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Transplantation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Kidney Transplantation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Kidney Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Kidney Transplantation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Kidney Transplantation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Kidney Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Kidney Transplantation Overview 10
Therapeutics Development 11
Pipeline Products for Kidney Transplantation - Overview 11
Pipeline Products for Kidney Transplantation - Comparative Analysis 12
Kidney Transplantation - Therapeutics under Development by Companies 13
Kidney Transplantation - Therapeutics under Investigation by Universities/Institutes 16
Kidney Transplantation - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Kidney Transplantation - Products under Development by Companies 21
Kidney Transplantation - Products under Investigation by Universities/Institutes 22
Kidney Transplantation - Companies Involved in Therapeutics Development 23
Kyowa Hakko Kirin Co., Ltd. 23
GlaxoSmithKline plc 24
Quark Pharmaceuticals, Inc. 25
Pharming Group N.V. 26
Grifols, S.A. 27
Novartis AG 28
Astellas Pharma Inc. 29
Shire Plc 30
Veloxis Pharmaceuticals A/S 31
La Jolla Pharmaceutical Company 32
Hansa Medical AB 33
Digna Biotech, S.L. 34
Viron Therapeutics, Inc. 35
Opsona Therapeutics Ltd. 36
Angion Biomedica Corp. 37
NovImmune SA 38
Tolera Therapeutics, Inc. 39
Bio-inRen 40
Kidney Transplantation - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 45
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
tacrolimus ER - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
voclosporin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
eculizumab - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ASKP-1240 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
belimumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
foralumab - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
cardiotrophin-1 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
C1 esterase inhibitor (human) - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
BB-3 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
QPI-1002 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
TOL-101 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
OPN-305 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
IgG-Degrading Enzyme of Streptococcus pyogenes - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
FCR-001 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Immucellgram - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
C1 esterase inhibitor (human) - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
CFZ-533 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
VT-111a - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
VT-214 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
C1 esterase inhibitor (recombinant) - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
LJPC-101 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
AS-2521780 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
FFP-106 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
ETR-002 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Cell Therapy for Kidney Transplantation - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
T-Cell Therapy for Kidney Transplant - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
BRN-1889 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
albumin (human) - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Kidney Transplantation - Recent Pipeline Updates 104
Kidney Transplantation - Dormant Projects 129
Kidney Transplantation - Discontinued Products 130
Kidney Transplantation - Product Development Milestones 131
Featured News & Press Releases 131
Jul 28, 2014: Quark Pharmaceuticals Reports Favorable Results From Phase II Clinical Trial Evaluating Investigational siRNA QPI-1002 131
Jul 28, 2014: Envarsus Receives European Marketing Authorization for Treatment of Both Kidney and Liver Transplant Patients 132
Jun 30, 2014: Envarsus XR Demonstrates Lower Treatment Failure Rate in African-Americans Compared to Twice-Daily Tacrolimus 133
Jun 23, 2014: Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients 135
Jun 03, 2014: Veloxis Announces Senior Level Appointments in Preparation for U.S. Commercialization of Envarsus XR (tacrolimus extended-release tablets) 136
May 22, 2014: Veloxis Receives Positive Opinion from CHMP for Envarsus for Treatment of Both Kidney and Liver Transplant Patients 137
Mar 13, 2014: U.S. FDA Accepts Veloxis' New Drug Application for Envarsus for the Prevention of Organ Rejection in Kidney Transplant Patients 138
Jan 21, 2014: FDA Grants Orphan Drug Designation to Soliris for Prevention of Delayed Graft Function in Renal Transplant Patients 139
Jan 09, 2014: Mylan Launches Generic Myfortic Delayed-Release Tablets 140
Jan 08, 2014: Veloxis Pharmaceuticals Receives Notice of Allowance from U.S. Patent Office for Diurnal-Independent Administration of Envarsus 140
Appendix 142
Methodology 142
Coverage 142
Secondary Research 142
Primary Research 142
Expert Panel Validation 142
Contact Us 143
Disclaimer 143

List of Tables
Number of Products under Development for Kidney Transplantation, H2 2014 11
Number of Products under Development for Kidney Transplantation - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Comparative Analysis by Unknown Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Investigation by Universities/Institutes, H2 2014 22
Kidney Transplantation - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 23
Kidney Transplantation - Pipeline by GlaxoSmithKline plc, H2 2014 24
Kidney Transplantation - Pipeline by Quark Pharmaceuticals, Inc., H2 2014 25
Kidney Transplantation - Pipeline by Pharming Group N.V., H2 2014 26
Kidney Transplantation - Pipeline by Grifols, S.A., H2 2014 27
Kidney Transplantation - Pipeline by Novartis AG, H2 2014 28
Kidney Transplantation - Pipeline by Astellas Pharma Inc., H2 2014 29
Kidney Transplantation - Pipeline by Shire Plc, H2 2014 30
Kidney Transplantation - Pipeline by Veloxis Pharmaceuticals A/S, H2 2014 31
Kidney Transplantation - Pipeline by La Jolla Pharmaceutical Company, H2 2014 32
Kidney Transplantation - Pipeline by Hansa Medical AB, H2 2014 33
Kidney Transplantation - Pipeline by Digna Biotech, S.L., H2 2014 34
Kidney Transplantation - Pipeline by Viron Therapeutics, Inc., H2 2014 35
Kidney Transplantation - Pipeline by Opsona Therapeutics Ltd., H2 2014 36
Kidney Transplantation - Pipeline by Angion Biomedica Corp., H2 2014 37
Kidney Transplantation - Pipeline by NovImmune SA, H2 2014 38
Kidney Transplantation - Pipeline by Tolera Therapeutics, Inc., H2 2014 39
Kidney Transplantation - Pipeline by Bio-inRen, H2 2014 40
Assessment by Monotherapy Products, H2 2014 41
Number of Products by Stage and Target, H2 2014 44
Number of Products by Stage and Mechanism of Action, H2 2014 47
Number of Products by Stage and Route of Administration, H2 2014 49
Number of Products by Stage and Molecule Type, H2 2014 51
Kidney Transplantation Therapeutics - Recent Pipeline Updates, H2 2014 104
Kidney Transplantation - Dormant Projects, H2 2014 129
Kidney Transplantation - Discontinued Products, H2 2014 130